Literature DB >> 25304616

Expression of RINT1 predicts seizure occurrence and outcomes in patients with low-grade gliomas.

Xing Fan1, Yin-yan Wang, Chuan-bao Zhang, Gan You, Ming-yang Li, Lei Wang, Tao Jiang.   

Abstract

PURPOSE: Most patients with low-grade gliomas (LGGs) experience epileptic seizures as an initial symptom. However, the mechanism of LGG-related epilepsy is poorly understood. Genetic changes in brain tumors influence epileptic seizures, but few biomarkers have been associated with LGG-related seizures. We investigated the association between LGG-related epilepsy and tumor-specific molecular changes.
METHODS: Clinical characteristics, RNA sequence data, and case follow-up data were reviewed for 76 patients with histologically confirmed LGG. Gene expression (n = 21,469) was compared between patients with preoperative epileptic seizures and those without preoperative epileptic seizures. The Engel classification was used at 6 months after surgery to evaluate the prognostic role of genes that passed the screen.
RESULTS: Expression of RAD50 interactor 1 (RINT1) significantly differed between LGG patients with and without preoperative epileptic seizures (p = 0.003). This result was validated by applying the same analysis to RNA sequence data from The Cancer Genome Atlas (p = 0.048). Patients with high RINT1 expression were at increased risk of LGG-related seizures compared to those with low expression (p = 0.044). RINT1 was also identified as a predictor of seizure outcomes in patients with LGG at 6 months after tumor resection (p = 0.022).
CONCLUSIONS: Our results suggest that high RINT1 expression may represent a risk factor for LGG-related seizures and may be associated with seizure outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25304616     DOI: 10.1007/s00432-014-1827-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

Review 1.  Analysing biological pathways in genome-wide association studies.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nat Rev Genet       Date:  2010-12       Impact factor: 53.242

Review 2.  Genome-wide association studies for common diseases and complex traits.

Authors:  Joel N Hirschhorn; Mark J Daly
Journal:  Nat Rev Genet       Date:  2005-02       Impact factor: 53.242

3.  Mapping and quantifying mammalian transcriptomes by RNA-Seq.

Authors:  Ali Mortazavi; Brian A Williams; Kenneth McCue; Lorian Schaeffer; Barbara Wold
Journal:  Nat Methods       Date:  2008-05-30       Impact factor: 28.547

4.  Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study.

Authors:  Gan You; Zhi-Yi Sha; Wei Yan; Wei Zhang; Yong-Zhi Wang; Shao-Wu Li; Lin Sang; Zi Wang; Gui-Lin Li; Shou-Wei Li; Yi-Jun Song; Chun-Sheng Kang; Tao Jiang
Journal:  Neuro Oncol       Date:  2011-12-19       Impact factor: 12.300

Review 5.  Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.

Authors:  Melanie S M van Breemen; Erik B Wilms; Charles J Vecht
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

Review 6.  Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment.

Authors:  Marjolein de Groot; Jaap C Reijneveld; Eleonora Aronica; Jan J Heimans
Journal:  Brain       Date:  2011-12-13       Impact factor: 13.501

7.  Resective surgery for intractable focal epilepsy in patients with low IQ: predictors for seizure control and outcome with respect to seizures and neuropsychological and psychosocial functioning.

Authors:  Helge Bjørnaes; Kirsten Engberg Stabell; Einar Heminghyt; Geir Ketil Røste; Søren Jacob Bakke
Journal:  Epilepsia       Date:  2004-02       Impact factor: 5.864

8.  BCL2A1 is a potential biomarker for postoperative seizure control in patients with low-grade gliomas.

Authors:  Gan You; Lin Feng; Wei Yan; Wei Zhang; Yong-Zhi Wang; Shao-Wu Li; Shou-Wei Li; Gui-Lin Li; Yi-Jun Song; Chun-Sheng Kang; Yong-Ping You; Tao Jiang
Journal:  CNS Neurosci Ther       Date:  2013-07-10       Impact factor: 5.243

9.  LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway.

Authors:  Padmaja Kunapuli; Chitta S Kasyapa; Lesleyann Hawthorn; John K Cowell
Journal:  J Biol Chem       Date:  2004-03-26       Impact factor: 5.157

10.  The significance of IDH1 mutations in tumor-associated seizure in 60 Chinese patients with low-grade gliomas.

Authors:  Ruofei Liang; Yingjun Fan; Xiang Wang; Qing Mao; Yanhui Liu
Journal:  ScientificWorldJournal       Date:  2013-11-13
View more
  3 in total

Review 1.  Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy.

Authors:  Shuli Liang; Xing Fan; Ming Zhao; Xia Shan; Wenling Li; Ping Ding; Gan You; Zhen Hong; Xuejun Yang; Guoming Luan; Wenbin Ma; Hui Yang; Yongpin You; Tianming Yang; Liang Li; Weiping Liao; Lei Wang; Xun Wu; Xinguang Yu; Jianguo Zhang; Qing Mao; Yuping Wang; Wenbin Li; Xuefeng Wang; Chuanlu Jiang; Xiaoyan Liu; Songtao Qi; Xingzhou Liu; Yan Qu; Jiwen Xu; Weimin Wang; Zhi Song; Jinsong Wu; Zhixiong Liu; Ling Chen; Yuanxiang Lin; Jian Zhou; Xianzeng Liu; Wei Zhang; Shichuo Li; Tao Jiang
Journal:  Cancer Med       Date:  2019-06-26       Impact factor: 4.452

2.  Younger age at surgery and lesser seizure frequency as prognostic factors for favorable seizure-related outcome after glioma resection in adults.

Authors:  Zhe-Ren Tan; Xiao-Yan Long; Zhi-Quan Yang; Jun Huang; Qing-Yuan Hu; Hao-Dong Yang; Guo-Liang Li
Journal:  Oncotarget       Date:  2017-06-27

3.  ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas.

Authors:  Xing Fan; Yongheng Wang; Chuanbao Zhang; Li Liu; Sen Yang; Yinyan Wang; Xing Liu; Zenghui Qian; Shengyu Fang; Hui Qiao; Tao Jiang
Journal:  Int J Mol Sci       Date:  2016-08-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.